Todd Watanabe has sold ARQT and made no open-market buys since Nov 2025

Todd Franklin Watanabe is the President, Chief Executive Officer, and a Class III director of Arcutis Biotherapeutics, Inc. (ARQT), positions he has held since April 2017.( At 57 years old, he has led the company through significant milestones, including multiple product launches for ZORYVE indications, achieving $166.5 million in net product revenue in 2024 (+471% YoY), and 128% attainment of corporate goals, despite a net loss of $(140.0) million.(

Watanabe brings extensive biotech experience from prior roles such as Co-founder and Chief Operating Officer at Kanan Therapeutics (2015–2018), VP of Strategy & Corporate Development at Kythera Biopharma (2013–2015), and various executive positions at Amgen (2005–2013) focusing on development and marketing for products like Repatha, Aimovig, and Enbrel.( Earlier, he worked at Eli Lilly and in the U.S. Government, complemented by 25 years as a U.S. Navy Reserve officer. He holds an M.A. in National Security Studies and a B.A. in International Relations from Georgetown University.( Recently, as a corporate insider, Watanabe has conducted stock transactions, including sales of shares under a 10b5-1 plan (e.g., 49,990 shares for ~$1.5M, 37,349 shares for tax withholding in March 2026), while retaining significant direct and indirect ownership.(

Written by Perplexity from public sources.